分子诊断在结直肠癌术后治疗中的应用

Molecular Diagnostic Applications in the Postoperative Treatment of Colorectal Cancer

目的探讨分子诊断在结直肠癌术后治疗中的应用及其意义。方法回顾性分析34例结直肠癌患者的临床病理资料,检测DNA切除修复交叉互补基因1(ERCC1)mRNA、胸苷酸合成酶(TYMS)mRNA水平以及二氢嘧啶脱氢酶(DPYD)、尿苷二磷酸葡萄糖醛酸转移酶1A1(UGT1A1)基因多态性。结果 ERCC1、TYMS mRNA高表达分别占67.6%、52.9%,其中ERCC1 mRNA表达水平与淋巴结转移数目呈负相关。DPYD、UGT1A1突变率分别为26.0%、30.4%,UGT1A1突变率与肿瘤肿瘤分化程度成负相关。结论分子诊断在结直肠癌术后治疗方案选择中具有重要指导意义。

Objective To investigate the molecular diagnostic applications and its significance in the postoperative treatment of colorectal cancer.Methods The clinical data of 34 cases of colorectal cancer,expression levels of the excision repair cross-complementing,group 1(ERCC1) mRNA and thymidylate synthetase(TYMS) mRNA,mutation rate of dihydropyrimidine dehydrogenase gene(DPYD),uridine diphosphoglucu-ronosyl transferase 1A1(UGT1A1) were analyzed retrospectively.Results High expressions of ERCC1 and TYMS mRNA were 67.6%and 52.9%,ERCC1 mRNA expression level was negatively correlated with the number of metastatic lymph nodes.The DPYD,UGT1A1 mutation rates were 26.0%,30.4%,the UGT1A1 mutation rate was negatively correlated with tumor differentiation of tumor.Conclusion Molecular diagnostics has the guiding significance in the postoperative treatment of colorectal cancer.